

2018 EMERGING THERAPIES FOR PBC, NASH AND ESLD SEMINAR SERIES

Washington, DC – April 28, 2018

Conference Location	Embassy Suites by Hilton Alexandria Old Town 1900 Diagonal Road Alexandria, Virginia, 22314	Phone: (703)-684-5900 http://embassysuites3.hilton.com/en/hotels/virginia/embassy-suites-by-hilton-alexandria-old-town-WASOTES/index.html
----------------------------	--	---

Parking at the Conference	A discounted parking rate of \$10 is available for all participants. Once you enter the self-parking area, bring the parking ticket to the Seminar Registration Desk
----------------------------------	---

Driving Directions	<ul style="list-style-type: none"> • Take 14th Street Bridge to 395 South. • Exit King Street East. Follow King Street approximately 3 miles. • You will pass the George Washington Masonic Temple, go under the train overpass and take right onto Diagonal Road • The hotel will be on the left
---------------------------	---

Seminar Agenda and Syllabus Information	Registration and breakfast begin at 7:30 a.m. in the Virginia Ballroom . Please check signage for any last minute room changes. The Emerging Therapies seminar is a paperless program. The course syllabus and related materials will be made available on a digital app that can be accessed by a smart phone, tablet device or personal computer. Instructions to download the <i>App</i> will be provided to participants in advance of the seminar. Wi-Fi will be available without charge.
--	--

7:30 am	Registration, Continental Breakfast & View Exhibits
8:00am	Welcome and Pre-Test
8:20 am	End Stage Liver Disease: Treatment, Managing Complications and Transplant <ul style="list-style-type: none"> • Staging, workup, and diagnosis of cirrhosis • Medical care of the patient with end stage liver disease Liver Transplantation <ul style="list-style-type: none"> • Listing Criteria and MELD Exceptions Case Study 1 – Cirrhosis and Encephalopathy
9:20 am	Hepatocellular Carcinoma <ul style="list-style-type: none"> • Screening diagnostic serum assays and imaging tests • Diagnosis without histology • Treatment and management options: Ablation, TACE and Surgery
10:00 am	Break & View Exhibits
10:15 am	Hepatocellular Carcinoma: New Systemic Treatment Options <ul style="list-style-type: none"> • Currently FDA Approved Therapies • New chemotherapy regimens in development and testing • Immunotherapy as the new MoA for HCC Case Study 2 – Diagnosis and Treatment of Hepatocellular Carcinoma

11:00 am	Primary Sclerosing Cholangitis (PSC) <ul style="list-style-type: none"> • Epidemiology • Ursodiol and Antibiotic Treatments • Predicting Outcomes and Improving Survival
11:40 am	New Treatments for PBC <ul style="list-style-type: none"> • Causes and Markers of PBC • Treatment Management • Ursodeoxycholic Acid (UDCA) and Obeticholic Acid Case Study 3 - PBC with inadequate response to Ursodiol
12:00 pm	Lunch & View Exhibits
12:30 am	The Best Use of Non-Invasive Imaging for Fibrosis Assessment <ul style="list-style-type: none"> • Technologies, Procedures and Outcomes
1:00 pm	NAFLD, LAL-D and NASH <ul style="list-style-type: none"> • Epidemiology and Demographics • Diagnosis and Evaluation • Treatment of Patients with Lysosomal Acid Lipase Deficiency (LAL-D) Causing Adult Fatty Liver • Conventional treatments
1:45 pm	Break & View Exhibits
2:00 pm	NASH Treatments in Development <ul style="list-style-type: none"> • Life Style Changes • Drugs in Clinical development for NASH Case Study 4 - NASH Diagnosis and Treatment
3:00pm	Post-test
3:15 pm	Adjourn

Attendee Cancellation, Substitution, Refund

The course tuition is refundable, minus a \$20 processing fee, if your cancellation is received in writing no later than seven days prior to the conference. Attendee substitutions are allowed, but notification must be made in writing seven days prior to the conference. After that date, no refunds, credits, or substitutions will be granted. No refunds or credits will be given to those who “no show.”

Recording and Photography

The University of Louisville reserves exclusive rights to record (audio and video) and/or photograph conference proceedings for use in marketing materials, future presentations and other purposes.

Attendance Policies

Guest Attendance

All conference activities (including educational sessions, meal functions, exhibit hall participation and others) are exclusively reserved for seminar participants. Non-registered guests (including children, family members, colleagues and others.) are not permitted in the seminar areas.

Conference Modification or Cancellation

The University of Louisville and SC Liver Research Consortium reserve the right to modify the course’s schedule, faculty or content if necessary. They also reserve the right to cancel this seminar, and in the unlikely event, a full refund of the registration fee will be provided. We are unable to refund any travel costs (flight, hotel, etc.) in the case of a seminar cancellation.

CME Information

Physicians (MD/DO) - The University of Louisville Office of Continuing Medical Education & Professional Development designates this live activity for a maximum of 6.0 *AMA PRA Category 1 Credit(s)*TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses - This program has been approved by the Kentucky Board of Nursing for 7.2 continuing education credits through University of Louisville Hospital, provider number 4-0068-7-16-878. The Kentucky Board

of Nursing approval of an individual nursing education provide does not constitute endorsement of program content.

Nurse Practitioners and Physician Assistants - AANP and AAPA accept Category I credit from AMA PRA Category 1 Credit(s)[™] organizations accredited by ACCME.

**Your Seminar
Faculty**



ZOBAIR M. YOUNOSSI, MD, MPH, FACG, FACP

Zobair M. Younossi, MD, MPH, is the Chairman, Department of Medicine, Inova Fairfax Medical Campus and Vice President for Research of Inova Health System. He is also Professor of Medicine, Virginia Commonwealth University, Inova Campus and Affiliate Professor of Biomedical Sciences at George Mason University.

Dr. Younossi served as the Staff Hepatologist and Senior Researcher at the Cleveland Clinic Foundation, Cleveland, Ohio (1995–2000). In 2000, Dr. Younossi was recruited to establish Inova’s Center for Liver Diseases. The center is currently well known for its excellence in clinical hepatology, teaching, and research. Inova’s Center for Liver Diseases is not only involved in “cutting-edge” clinical trial protocols and outcomes research projects, but also has pioneered research in genomics and proteomics of obesity and its related liver diseases. The center has participated in over 90 research projects in translational research, outcomes research, and “cutting edge” clinical trials.




KIRTI SHETTY, MD, FACG

Dr. Kirti Shetty is currently Associate Professor of Medicine at Johns Hopkins University and an Adjunct Professor of Medicine and Surgery at Georgetown University. She is also the Director of Hepatology at Silbey Memorial Hospital in Washington, DC.

Her clinical interests include viral hepatitis, nonalcoholic fatty liver disease, liver cancer and liver transplantation outcomes. Dr. Shetty’s research focuses on mechanisms of hepatocarcinogenesis in cirrhosis. Her ongoing translational research collaborations explore biomarkers for hepatocellular carcinoma and chemopreventive approaches in patients with cirrhosis.

Dr. Shetty has authored numerous publications in prestigious journals and has both contributed to and edited textbooks in liver disease. She attained her medical degree at Christian Medical College in Vellore, India.



BRIAN LAM, MSHS, PA-C

As a physician assistant and research investigator in Northern Virginia, Brian Lam has enjoyed the privilege of working in hepatology for over a decade. From translational research to clinical trials and routine clinical care, he has been privileged to work with an exceptional team at Inova Health System’s Beatty Liver and Obesity Research Program and Center for Liver Disease.

Brian also has particular interests in non-alcoholic steatohepatitis and

cholestatic liver diseases; he serves as an investigator in multicenter clinical trials and in Inova's research projects in these areas. Brian looks forward to the advances in hepatology to come in the upcoming years.
